News | December 03, 2007

Drug-Eluting Stents Improve Patient Outcomes in Routine Practice

December 4, 2007 - In general, drug-eluting stents (DES) achieve better results than bare-metal stents do, U.S. researchers report in the November 20 issue of the Journal of the American College of Cardiology.

"We found that DES, as they are being used in clinical practice in North America, significantly reduce the need for target vessel revascularization compared to bare-metal stents," lead investigator J. Dawn Abbott, M.D., told Reuters Health.

"Importantly," she added, this reduction "was observed in patients with and without complex coronary lesion types."

Dr. Abbott of Rhode Island Hospital, Providence, and colleagues studied data from 2004 for 1460 patients who received at least one DES. These data were compared with earlier records for 1,763 patients who received at least one bare-metal stent.

At one year, the cumulative death and myocardial infarction rate was 7.6 percent in DES patients and 8.7 percent in bare-metal stent patients, a nonsignificant difference. The corresponding rate of target vessel revascularization at one year was 5.0 percent and 9.2 percent (p

In DES patients, the one-year hazard ratio for any repeat vascularization by percutaneous coronary intervention or coronary bypass was 0.38, and the rate of stent thrombosis was 1 percent.

"These improved outcomes," continued Dr. Abbott, "were achieved without any evidence of increased hazard from DES use, as demonstrated by similar one-year rates of death and myocardial infarction, and a very low rate of angiographically confirmed late stent thrombosis."

"While these results certainly confirm the efficacy of DES," she concluded, "we will need longer follow-up to evaluate the incidence of very late stent thrombosis in these patients."

In an accompanying editorial, Franz-Josef Neumann, M.D., Herz-Zentrum, Bad Krozingen, Germany writes that the "mounting evidence on this matter confirms the superior efficacy of DES with respect to the prevention of repeat revascularization and does not suggest inferior safety compared with bare-metal stents."

Ref: J Am Coll Cardiol 2007;50:2029-2038
Source: Reuters Health, December 3, 2007

For more information:

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init